The Alzheimer’s Association is accepting application for its Part the Cloud Translational Research Funding initiative.
While many academic investigators and companies have successfully discovered candidate therapeutics and have succeeded in the preclinical stages of development, moving to human testing can be a major stumbling block. Most government and nongovernment grant mechanisms support preclinical development or mid- to latter clinical trials testing drug efficacy in humans, but there are few mechanisms for supporting the critical earlier human phase studies.
Through this call for proposals. the Alzheimer’s Association aims to fill the gap in Alzheimer’s disease drug development by providing support for early-phase studies of potential Alzheimer’s therapeutics, including the validation of biological markers of disease progression in the context of evaluating a potential therapy.
Through the initiative, AA expects to award four grants of up to $750,000 over two to three years to academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior (Phase 1) to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans. The award is intended to support Phase 1 studies or pilot small-scale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer’s disease (i.e., early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment.
Letters of intent are due May 23. Upon review, selected applicants will be invited to submit a full proposal by July 31, 2019.
Eligible applicants include nonprofit and small for-profit agencies. Researchers with full-time staff or faculty appointments are encouraged to apply. Applications from postdoctoral candidates will not be accepted.
See the Alzheimer’s Association website for complete program guidelines and application instructions.